Kathleen Clark

President Trump purchased between $680,000 and $1.18 million in stock in Eli Lilly and West Pharmaceutical Services in early 2025, shortly before the administration implemented policies that significantly benefited these companies, including advancing Medicare reimbursement for GLP-1 drugs and cracking down on cheaper generic competitors. Government ethics experts have raised concerns that the stock purchases undermine public trust by creating the appearance that Trump is personally profiting from administration actions. Congressional Democrats are calling for legislation to ban presidents from owning and trading stocks.